Skinny Labels, Big Savings Act
SB 43, the “Skinny Labels, Big Savings Act,” would amend federal patent law to create a safe harbor from infringement claims for certain drug and biologic manufacturers that seek FDA approval for products with “skinny labels.” The bill targets method-of-use patents and specifies that filing or seeking approval of abbreviated new drug applications, 505(b)(2) applications, and biosimilar applications would not count as direct, induced, or contributory infringement when the applicant uses labeling that omits the patented use.
The bill also protects related post-approval conduct, including promoting or commercially marketing the approved product and describing it as generic, therapeutically equivalent, biosimilar, or interchangeable, so long as the labeling and marketing do not reference the patented condition of use identified by the patent owner. It applies to both drug products and biological products, and it defines key terms by reference to existing FDA and patent-law provisions. The legislation is written to apply retroactively to conduct and pending proceedings on or after enactment.
If enacted, SB 43 would narrow the circumstances under which generic drug makers, 505(b)(2) applicants, and biosimilar manufacturers can be sued for patent infringement based on method-of-use patents. It would effectively strengthen the legal protection for “skinny label” strategies by clarifying that certain FDA approval efforts, labeling, promotion, and marketing activities are not infringing when they avoid the patented use. The bill would amend 35 U.S.C. 271 and interact directly with FDA labeling and patent-listing procedures under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act, affecting patent holders, generic manufacturers, biosimilar sponsors, and FDA-regulated drug marketing practices.
The available context suggests a generally bipartisan and pro-competition posture toward the bill, as indicated by the cross-party sponsorship from Senators Hickenlooper, Welch, Cotton, and Collins. The bill’s title and structure frame it as a cost-saving measure aimed at preserving access to lower-cost medicines while respecting patent boundaries. No committee transcript or vote record is available here, so there is no documented floor or committee debate to indicate broader opposition or support beyond the sponsors.
The main point of contention is likely the balance between lowering drug costs and preserving patent rights. Supporters would view the bill as preventing patent owners from using method-of-use claims to block generic and biosimilar competition when the competing product does not seek approval for the patented use. Opponents, likely among brand-name drug and biologics patent holders, may argue that the bill weakens enforcement of valid patents and could encourage marketing that indirectly erodes exclusivity. The bill’s retroactive application and its treatment of promotion and commercial marketing could also be disputed because they may affect pending litigation and the scope of infringement liability.